Akebia Therapeutics, Inc. - stock earnings
AKBA Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| Aug. 23, 2024 BeforeMarket | - / - | 45.8 million | - / 49.5 million | 54.0 million |
AKBA Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q1 | -18.0 million USD | 32.6 million USD |
| 2023Q4 | 614000 USD | 56.2 million USD |
| 2023Q3 | -14.5 million USD | 42.0 million USD |
| 2023Q2 | -11.2 million USD | 56.4 million USD |
| 2023Q1 | -16.7 million USD | 40.1 million USD |
| 2022Q4 | -8.8 million USD | 55.2 million USD |
| 2022Q3 | -55.7 million USD | 49.0 million USD |
| 2022Q2 | 29.3 million USD | 126.8 million USD |
| 2022Q1 | -66.3 million USD | 61.7 million USD |
| 2021Q4 | -70.7 million USD | 59.6 million USD |
| 2021Q3 | -59.5 million USD | 48.8 million USD |
| 2021Q2 | -83.0 million USD | 52.9 million USD |
| 2021Q1 | -69.6 million USD | 52.3 million USD |
| 2020Q4 | -87.0 million USD | 56.7 million USD |
| 2020Q3 | -60.0 million USD | 60.0 million USD |
| 2020Q2 | -175.8 million USD | 90.1 million USD |
| 2020Q1 | -60.7 million USD | 88.5 million USD |
| 2019Q4 | -94.5 million USD | 69.6 million USD |
| 2019Q3 | -54.6 million USD | 92.0 million USD |
| 2019Q2 | -58.2 million USD | 100.8 million USD |
| 2019Q1 | -72.4 million USD | 72.7 million USD |
| 2018Q4 | -88.4 million USD | 59.9 million USD |
| 2018Q3 | -26.0 million USD | 53.2 million USD |
| 2018Q2 | -34.1 million USD | 48.8 million USD |
| 2018Q1 | -23.4 million USD | 45.9 million USD |
| 2017Q4 | 12.3 million USD | 87.3 million USD |
| 2017Q3 | -23.1 million USD | 41.3 million USD |
| 2017Q2 | -21.5 million USD | 28.5 million USD |
| 2017Q1 | -44.5 million USD | 20.9 million USD |
| 2016Q4 | -37.9 million USD | 1.5 million USD |
| 2016Q3 | -36.3 million USD | ? USD |
| 2016Q2 | -35.8 million USD | ? USD |
| 2016Q1 | -25.8 million USD | ? USD |
| 2015Q4 | -19.9 million USD | ? USD |
| 2015Q3 | -19.5 million USD | 64000 USD |
| 2015Q2 | -10.7 million USD | 84000 USD |
| 2015Q1 | -10.7 million USD | 105000 USD |
| 2014Q4 | -10.4 million USD | 349006 USD |
| 2014Q3 | -9.3 million USD | 180000 USD |
| 2014Q2 | -7.6 million USD | 171227 USD |
| 2014Q1 | -9.7 million USD | ? USD |
| 2013Q4 | -5.9 million USD | ? USD |
| 2013Q3 | -3.8 million USD | ? USD |
| 2013Q2 | -2.8 million USD | ? USD |
| 2013Q1 | -620914 USD | ? USD |
| 2012Q4 | -3.3 million USD | ? USD |
AKBA Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -51.9 million USD | 194.6 million USD |
| 2022 | -106.0 million USD | 292.6 million USD |
| 2021 | -244.9 million USD | 213.6 million USD |
| 2020 | -349.9 million USD | 295.3 million USD |
| 2019 | -279.7 million USD | 335.0 million USD |
| 2018 | -171.9 million USD | 207.7 million USD |
| 2017 | -76.9 million USD | 178.0 million USD |
| 2016 | -135.7 million USD | 1.5 million USD |
| 2015 | -60.7 million USD | ? USD |
| 2014 | -37.0 million USD | 700233 USD |
| 2013 | -13.2 million USD | ? USD |
| 2012 | -8.2 million USD | ? USD |
AKBA
Price: $1.15
52 week price:
Earnings Per Share: -0.28 USD
P/E Ratio: -5.32
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.3 million
Ebitda: -24.0 millionMarket Capitalization: 270.4 million